Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell …

Y Yu, FY Meng, X Wei, X Chen, H Li, Q Liu, C Li… - The Journal of Thoracic …, 2024 - Elsevier
Background To date, few studies have compared effectiveness and survival rates of
neoadjuvant chemotherapy combined with immunotherapy (NACI) and conventional …
被引用次数：8 相关文章

Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell …

YK Yu, FY Meng, XF Wei, XK Chen… - The Journal of … - pubmed.ncbi.nlm.nih.gov
Background To date, few studies have compared effectiveness and survival rates of
neoadjuvant chemotherapy combined with immunotherapy (NACI) and conventional …

Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell …

Y Yu, FY Meng, X Wei, X Chen, H Li, Q Liu, C Li… - The Journal of Thoracic … - jtcvs.org
Background To date, few studies have compared effectiveness and survival rates of
neoadjuvant chemotherapy combined with immunotherapy (NACI) and conventional …

Neoadjuvant Chemotherapy Combined with Immunotherapy versus Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell …

YK Yu, FY Meng, XF Wei, XK Chen, HM Li… - The Journal of …, 2024 - europepmc.org
Background Currently, few studies have conducted a comparison between the effectiveness
and survival of neoadjuvant chemotherapy combined with immunotherapy (NACI) and …